 The investigators now propose a phase II, controlled, single blind and randomised efficacy study n40 in 2 parallel groups. 1 group transdermal nicotine-therapy 1 control group without additional therapy The main objective is to verify the correlation between UPDRS score III motor score and the administrated nicotine dose. This study will also allow the evaluation of nicotine neuroprotective effect. The incrementation phase by weekly steps of 5 mg until 20 mg, then 10 mg to reach 90 mgj or the maximal tolerated dose, will last on 11 weeks and will be followed by a 28 weeks phase at this stable dose. After this maximal dose plateau phase, treatment will be progressively decreased by 15 mg weekly steps, over a de 6-week period followed by a five-week wash out phase. 